Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Mar 08, 2024 7:41am

138 Views

Post# 35922227

RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

Even for Clinical Trial supplies, Pela will still have to be compliant with a validated manufacturing process... ONCY has had 25 years on this... they have their manufacturing process in place... This was nothing new.

And to suggest that this means Pela is a lot closer to be being acquired is misleading. there is no inference here at all...

Another nothing burger from the pumpers.

<< Previous

Bullboard Posts

Next >>

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!